Davita Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while YieldMax NVDA Option Income Strategy ETF trades at $12.79. The key difference: Davita Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| DVA | NVDY | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $240.96 | $17.96 |
52-Week Low | $103.87 | $11.58 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
NVDY trades at $13.00, up 1.72% with a bullish technical signal from moving averages. The ETF generates weekly dividend distributions ranging from $0.09 to $0.15, providing consistent income. Recent news highlights the fund's strategy of selling NVIDIA call options to fund distributions while potentially capping upside. Technical indicators show mixed signals with RSI at extreme levels suggesting potential overbought conditions.
The outlook balances income generation against opportunity cost. While weekly distributions offer attractive yield, the strategy may limit participation in NVIDIA's full growth potential. Key risks include the fund's dependence on NVIDIA's volatility and the trade-off between income and capital appreciation. Investors seeking regular income may find value, but those prioritizing growth might prefer direct NVIDIA exposure.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →